Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 11Thoracic 8Genitourinary 7Gynecologic 6Dermatologic 5Head & Neck 3Other solid neoplasm 2Breast 2Tumor-Agnostic 1Sarcoma 1NET 1Lymphoid 1Endocrine 1

Conditions

Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Parotid Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroendocrine Tumors 1Microsatellite Instability 1Mesothelioma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoid Tumor 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Anus Neoplasms 1

Interventions

lutetium Lu 177 dotatate 2repotrectinib 1pralsetinib 1pembrolizumab 1entrectinib 1copper dotatate CU-64 1cabozantinib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Octreotide 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × pembrolizumab × NET × Clear all
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡